|1.||Macdonald, R Loch: 8 articles (06/2013 - 10/2003)|
|2.||Ilodigwe, Don: 3 articles (06/2013 - 01/2009)|
|3.||Steyerberg, Ewout W: 3 articles (10/2010 - 09/2002)|
|4.||Marshall, Lawrence F: 3 articles (02/2006 - 09/2002)|
|5.||Zausinger, Stefan: 3 articles (10/2004 - 06/2003)|
|6.||Schmid-Elsaesser, Robert: 3 articles (10/2004 - 06/2003)|
|7.||Torner, James: 2 articles (06/2013 - 01/2013)|
|8.||Murray, Gordon D: 2 articles (01/2013 - 02/2006)|
|9.||Tolentino, Jocelyn: 2 articles (02/2009 - 02/2007)|
|10.||Jang, Yeon Gyoe: 2 articles (02/2009 - 01/2009)|
|1.||Spinal Cord Injuries (Spinal Cord Injury)
12/01/1995 - "Tirilazad and related compounds have been found to be highly beneficial in spinal cord trauma. "
06/01/1993 - "One of these, tirilazad mesylate (U-74006F), has been shown to be quite effective in animal models of brain and spinal cord injury and is the subject of phase III clinical trials. "
05/01/1992 - "One of these, tirilazad mesylate (U-74006F), has been shown to be effective in animal models of brain and spinal cord injury and is currently the subject of phase II clinical trials. "
03/01/1992 - "Efficacy of the 21-aminosteroid U74006F in improving neurological recovery after spinal cord injury in rats."
01/01/1991 - "These results suggest that after weight-induced spinal cord trauma, U74006F is associated with improved neurologic function in moderately injured, but not severely injured animals."
|2.||Brain Ischemia (Cerebral Ischemia)
05/09/1994 - "The protective effects of the 21-aminosteroid tirilazad mesylate (U-74006F), one of the most efficacious inhibitors of free radical-initiated lipid peroxidation, against ischemic brain damage particularly in permanent focal cerebral ischemia still remain controversial. "
02/01/1997 - "These results document the neuroprotective efficacy of tirilazad mesylate in cerebral ischemia."
06/01/1999 - "Mortality rates and overall outcome, assessed using the Glasgow Outcome Scale at 3 months post-SAH, were not different between the two groups, despite a significantly lower incidence of delayed cerebral ischemia in patients given tirilazad. "
01/01/1996 - "Since tirilazad appears to have little or no behavioral or physiologic side effects, it appears to be an ideal agent for widespread brain ischemia prophylaxis. "
05/09/1994 - "Dose-response analysis of the effect of 21-aminosteroid tirilazad mesylate (U-74006F) upon neurological outcome and ischemic brain damage in permanent focal cerebral ischemia."
|3.||Subarachnoid Hemorrhage (Aneurysmal Subarachnoid Hemorrhage)
06/01/1999 - "To test the safety and efficacy of high-dose (15 mg/kg/day) tirilazad mesylate in women suffering from aneurysmal subarachnoid hemorrhage (SAH), a prospective randomized, double-blind, vehicle-controlled trial (parallel to the one conducted in Europe, Australia, New Zealand, and South Africa) was performed at 65 North American neurosurgical centers. "
10/01/1997 - "These results suggest that gender differences do not significantly effect the blood-brain barrier protective efficacy of tirilazad following subarachnoid hemorrhage in the rat."
10/01/1997 - "The purpose of the present study was to compare the efficacy of tirilazad in attenuating early post-subarachnoid hemorrhage-induced blood-brain barrier damage in the rat, a species in which single-dose metabolism of the drug is comparable between males and females. "
03/01/1997 - "To test the safety and efficacy of tirilazad mesylate, a nonglucocorticoid 21-aminosteroid, in improving the outcome of patients with aneurysmal subarachnoid hemorrhage (SAH), 902 patients were enrolled in a prospective randomized, double-blind, vehicle-controlled trial at 54 North American neurosurgical centers. "
01/01/2013 - "The approach of Bayesian neural networks with fuzzy logic inferences was applied to data from five trials of Tirilazad for aneurysmal subarachnoid hemorrhage (3551 patients). "
02/01/2007 - "Systematic review and meta-analysis of studies describing the efficacy of tirilazad in animal models of focal ischemia, in which outcome was measured as infarct volume and/or neurological score. "
10/01/1994 - "Treatment with U-74006F (two bolus doses of 3 mg/kg each; the first dose was injected i.v. 30 min before ischemia and the second dose, at the time of reflow) reduced the hepatic injury by 60% at 4 hr of reperfusion, improved the survival rate from 18% to 55% and decreased the degree of hepatic injury at 48 hr of reperfusion. "
05/01/1996 - "However, U-74006F protected hepatocytes significantly against membrane damage induced by cell swelling due to perfusion with hypotonic medium or ischemia-reperfusion. "
05/01/1996 - "Treatment with U-74006F (two bolus doses of 3 mg/kg each; the first dose was injected i.v. 30 min before ischemia and the second dose, at the time of reflow) reduced hepatic injury by 60% but had no significant effect on either parameter of lipid peroxidation. "
01/01/1995 - "Thus, tirilazad acts during early reperfusion to prevent secondary metabolic decay associated with severe acidotic ischemia.(ABSTRACT TRUNCATED AT 250 WORDS)"
01/01/2001 - "To assess whether tirilazad mesylate is safe and effective at improving outcome in patients with acute ischaemic stroke. "
09/01/2000 - "We performed a systematic review of randomized, controlled trials that assessed the safety and efficacy of tirilazad in patients with acute ischemic stroke. "
09/01/2000 - "As a result, clinical studies were undertaken to assess the safety and efficacy of tirilazad in the treatment of acute ischemic stroke. "
02/01/2007 - "Systematic review and meta-analysis of the efficacy of tirilazad in experimental stroke."
11/01/1992 - "The efficacy of U74006F in reducing cerebral infarct size was investigated in a rabbit model of thromboembolic stroke. "
|5.||Glutamic Acid (Glutamate)
|7.||Dizocilpine Maleate (Dizocilpine)
|8.||N-Methyl-D-Aspartate Receptors (NMDA Receptors)
|1.||Transplantation (Transplant Recipients)
|2.||Drug Therapy (Chemotherapy)
|4.||Angioplasty (Angioplasty, Transluminal)